This site contains promotional content intended for Healthcare Professionals in Ireland and other relevant decision makers | Not a HCP? Visit our Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

  • Products
  • Therapy Area

About Beyonttra
®
▼ (acoramidis)

hallmark Icon

Beyonttra is indicated for the treatment of wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).

The only stabiliser with near-complete (≥90%) transthyretin (TTR) stabilisation in the label.

Key Messages
Key Messages

* Post-hoc analysis of all-cause mortality and recurrent CV hospitalisations (RRR: 0.58 [95% CI: 0.43-0.79]; p=0.0005) vs placebo at Month 30.

† RRR for frequency of cardiovascular-related hospitalisation per year was 0.496 (95% CI: 0.355-0.695) in favour of acoramidis; p < 0.0001; ARR: 15.9%.

Beyonttra®▼ (acoramidis) - About ATTR-CM
Learn more about transthyretin amyloid cardiomyopathy (ATTR-CM).
PP-BEY-IE-0035-1, November 2025
Beyonttra®▼ (acoramidis) - Mode of Action
Learn more about the Mode of Action of Beyonttra® (acoramidis).
PP-BEY-IE-0041-1, November 2025
Beyonttra®▼ (acoramidis) - Mechanism of Disease
Learn More about the Mechanism of Disease in ATTR-CM.
PP-BEY-IE-0040-1, November 2025

PP-BEY-IE-0031-1   |   November 2025

 

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professional are asked to report any suspected adverse reactions.